Chinese animal gene modifier set to close $79m funding

Animal gene modifier Beijing Biocytogen managed to draw on both government and private capital for its Series D funding round.

The Series D round values the Korean semiconductor startup at $2.9bn as it targets global commercialisation of its AI inference accelerator.

The digital bank, which has operations in China, Hong Kong and Indonesia, is looking at M&A opportunities and developing artificial intelligence agents, with the debt and equity fundraise.

Despite the decrease of car sales in China, upstream auto parts retailer Haoqipei is betting that customers want upgrades rather than new models.

Education platform Knowbox has received a new round of funding to develop cost-saving AI technology, but with regulations tightening, time is running out for these platforms to generate positive cash flows.

Helical Fusion and Celaid Therapeutics have raised JPY3.23bn and JPY400m, respectively, as Japanese capital targets research-intensive startups.